-transparent.png){kind=logo}
The pharmacokinetics of gentamicin were examined in two functionally anephric patients undergoing peritoneal dialysis (PD). Peritoneal dialysis effectively decreased the gentamicin half-life (t1/2 beta) by 73 and 78% while increasing total body clearance [QB(ml/min/kg] of gentamicin 4.3- and 3.4-fold. The appreciable variability in gentamicin pharmacokinetics among renal failure patients being peritoneally dialyzed may necessitate dosage adjustments based on rapid and accurate measurement of serum gentamicin concentrations.
Related Publications
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
May 1976,
Kidney international,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
January 1985,
Therapeutic drug monitoring,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
January 1986,
Nephron,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
April 1981,
Antimicrobial agents and chemotherapy,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
January 1986,
European journal of clinical pharmacology,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
February 1989,
Journal of clinical pharmacology,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
May 1987,
Pharmacology & toxicology,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
January 1973,
Acta clinica Belgica,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
August 2012,
Clinical journal of the American Society of Nephrology : CJASN,
S R Hamann, and
P R Oeltgen, and
W A Shank, and
R A Blouin, and
L Natarajan
October 1996,
Clinical pharmacokinetics,
